Article

Dosimetry-Driven Alpha Emitter Selection for Radioligand Therapy: Is daughter translocation a significant safety concern?

2025-08-11

Abstract excerpt

<h4>ABSTRACT</h4> <h4>PURPOSE</h4> The first long-term safety data with a 212 Pb-labelled radiopharmaceutical reported significant renal adverse events after more than two years of follow-up. Understanding the pharmacokinetic drivers of dose delivery for alpha emitting radioligand therapy (RLT) will be critical to optimizing molecules. We aimed to model and compare the dosimetry and therapeutic index (TI) of a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1cec20fd-53c0-5a0f-93a6-ffe90a8f23b2
DOI: 10.1101/2025.08.08.25333110

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Dosimetry-Driven Alpha Emitter Selection for Radioligand Therapy: Is daughter translocation a significant safety concern?DOI 10.1101/2025.08.08.25333110Read

National Cancer Institute Support for Targeted Alpha-Emitter TherapySemantic proximity Read

Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood CancersSemantic proximity Read

Radiopharmaceutical therapy for metastatic prostate cancer: Insights from mechanistic modeling and <i>in silico</i> trialsSemantic proximity Read

Factors Associated with Radiation Safety Clearance Following Lu-177 DOTATATE TherapySemantic proximity Read

CD46 targeted <sup>212</sup> Pb alpha particle radioimmunotherapy for prostate cancer treatmentSemantic proximity Read

Strategic Objectives of Nanotechnology-Driven Repurposing in Radiopharmacy. Implications for Radiopharmaceutical Repurposing (Beyond Oncology)Semantic proximity Read

Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical ModelsSemantic proximity Read

Guiding treatment response by spatiotemporal control of α-particle deposition in solid tumors: the case for ‘affinity cocktails’ of antibody-radioconjugatesSemantic proximity Read

Biodistribution-Driven Discovery Identifies a Glycosidase-Cleavable Linker to Reprogram RadiotheranosticsSemantic proximity Read

Comprehensive statistical analysis of the pharmacokinetics, safety and clinical benefit rate of MitoTam in a single-center phase I/Ib trial in patients with metastatic solid tumorsSemantic proximity Read

Bismuth-213 for Targeted Radionuclide Therapy: From Atom to BedsideSemantic proximity Read

<i>In vivo</i> tracking of <i>ex vivo</i> generated <sup>89</sup> Zr-oxine labeled plasma cells by PET in a non-human primate modelSemantic proximity Read